Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 282

2.

Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy.

Venderink W, Bomers JG, Overduin CG, Padhani AR, de Lauw GR, Sedelaar MJ, Barentsz JO.

Eur Urol. 2019 Nov 29. pii: S0302-2838(19)30775-4. doi: 10.1016/j.eururo.2019.10.009. [Epub ahead of print]

3.

Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation.

Israël B, Leest MV, Sedelaar M, Padhani AR, Zámecnik P, Barentsz JO.

Eur Urol. 2019 Nov 23. pii: S0302-2838(19)30823-1. doi: 10.1016/j.eururo.2019.10.024. [Epub ahead of print]

4.

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.

Westdorp H, Creemers JHA, van Oort IM, Schreibelt G, Gorris MAJ, Mehra N, Simons M, de Goede AL, van Rossum MM, Croockewit AJ, Figdor CG, Witjes JA, Aarntzen EHJG, Mus RDM, Brüning M, Petry K, Gotthardt M, Barentsz JO, de Vries IJM, Gerritsen WR.

J Immunother Cancer. 2019 Nov 14;7(1):302. doi: 10.1186/s40425-019-0787-6.

5.

Analysis of Magnetic Resonance Imaging-directed Biopsy Strategies for Changing the Paradigm of Prostate Cancer Diagnosis.

Schoots IG, Padhani AR, Rouvière O, Barentsz JO, Richenberg J.

Eur Urol Oncol. 2020 Feb;3(1):32-41. doi: 10.1016/j.euo.2019.10.001. Epub 2019 Nov 7.

PMID:
31706946
6.

Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition.

Engels RRM, Israël B, Padhani AR, Barentsz JO.

Eur Urol. 2019 Sep 30. pii: S0302-2838(19)30741-9. doi: 10.1016/j.eururo.2019.09.021. [Epub ahead of print]

7.

Complications and Adverse Events of Three Magnetic Resonance Imaging-based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial.

Wegelin O, Exterkate L, van der Leest M, Kelder JC, Bosch JLHR, Barentsz JO, Somford DM, van Melick HHE.

Eur Urol Oncol. 2019 Nov;2(6):617-624. doi: 10.1016/j.euo.2019.08.007. Epub 2019 Sep 11.

PMID:
31519516
9.

Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?

Exterkate L, Wegelin O, Barentsz JO, van der Leest MG, Kummer JA, Vreuls W, de Bruin PC, Bosch JLHR, van Melick HHE, Somford DM.

Eur Urol Oncol. 2019 Jun 22. pii: S2588-9311(19)30080-X. doi: 10.1016/j.euo.2019.06.005. [Epub ahead of print]

PMID:
31239236
10.

Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men.

Venderink W, van Luijtelaar A, van der Leest M, Barentsz JO, Jenniskens SFM, Sedelaar MJP, Hulsbergen-van de Kaa C, Overduin CG, Fütterer JJ.

BJU Int. 2019 Nov;124(5):775-784. doi: 10.1111/bju.14853. Epub 2019 Jul 23.

PMID:
31237388
11.

USPIO-enhanced MRI of pelvic lymph nodes at 7-T: preliminary experience.

Philips BWJ, Stijns RCH, Rietsch SHG, Brunheim S, Barentsz JO, Fortuin AS, Quick HH, Orzada S, Maas MC, Scheenen TWJ.

Eur Radiol. 2019 Dec;29(12):6529-6538. doi: 10.1007/s00330-019-06277-7. Epub 2019 Jun 14.

12.

PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway.

Padhani AR, Barentsz J, Villeirs G, Rosenkrantz AB, Margolis DJ, Turkbey B, Thoeny HC, Cornud F, Haider MA, Macura KJ, Tempany CM, Verma S, Weinreb JC.

Radiology. 2019 Aug;292(2):464-474. doi: 10.1148/radiol.2019182946. Epub 2019 Jun 11.

PMID:
31184561
13.
14.

High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility.

van der Leest M, Israël B, Cornel EB, Zámecnik P, Schoots IG, van der Lelij H, Padhani AR, Rovers M, van Oort I, Sedelaar M, Hulsbergen-van de Kaa C, Hannink G, Veltman J, Barentsz J.

Eur Urol. 2019 Nov;76(5):574-581. doi: 10.1016/j.eururo.2019.05.029. Epub 2019 Jun 2.

15.

Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.

Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J, Weinreb JC.

Eur Urol. 2019 Sep;76(3):340-351. doi: 10.1016/j.eururo.2019.02.033. Epub 2019 Mar 18. Review.

PMID:
30898406
16.
17.

Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: What We See and What We Miss.

Padhani AR, Haider MA, Villers A, Barentsz JO.

Eur Urol. 2019 May;75(5):721-722. doi: 10.1016/j.eururo.2018.12.004. Epub 2018 Dec 16. No abstract available.

PMID:
30563723
18.

The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.

Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, Bosch JLHR, Barentsz JO, Somford DM, van Melick HHE.

Eur Urol. 2019 Apr;75(4):582-590. doi: 10.1016/j.eururo.2018.11.040. Epub 2018 Dec 3.

PMID:
30522912
19.

Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.

van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, van den Hout H, van der Lelij H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M, Hulsbergen-van de Kaa C, Barentsz JO.

Eur Urol. 2019 Apr;75(4):570-578. doi: 10.1016/j.eururo.2018.11.023. Epub 2018 Nov 23.

Supplemental Content

Loading ...
Support Center